Results of the NEXT clinical trial Reported at TCT 2011

November 11, 2011

SAN FRANCISCO, CA - NOVEMBER 11, 2011 - Researchers have found that polymer-free amphilimus-eluting stents in de novo coronary artery lesions showed a significantly lower in-stent late loss at six months compared to paclitaxel-eluting stents with permanent polymers.

Results of the NEXT trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. NEXT is a prospective, randomized trial comparing a polymer-free amphilimus-eluting stent to a paclitaxel-eluting stent.

The risk/benefit balance of coronary drug-eluting stents is still suboptimal, and the safety of coating polymers, which hold and release the drug over time, remains uncertain. Researchers sought to demonstrate the non-inferiority of polymer-free amphilimus-eluting stents versus permanent-polymer paclitaxel-eluting stents in de novo native coronary artery lesions. The primary endpoint was six-month angiographic in-stent late loss within a non-inferiority scope. Late loss is the difference between the diameter of a stented segment post-procedure compared with the follow-up angiogram.

A total of 323 patients were enrolled, with 162 randomized to amphilimus-eluting stents and 161 to paclitaxel-eluting stents. In-stent late loss was significantly lower with amphilimus-eluting stents (0.14±0.36 mm vs. 0.34±0.40 mm, P<0.0001 for non-inferiority, P<0.0001 for superiority). Clinical endpoints (cardiac death, myocardial infarction, target lesion revascularization or stent thrombosis) up to 12 months did not differ significantly.

"These results are encouraging evidence that support the use of polymer-free stents, but further studies are warranted to prove that this potent polymer-free stent can improve the risk-benefit balance of coronary drug-eluting stents," said Didier Carrié, MD, PhD, the principal investigator of the trial. Dr. Carrié is Professor of Medicine, Cardiology at the University of Paul Sabatier and the Head of Hemodynamics and Angioplasty Section at Rangueil Hospital in Toulouse, France.
The NEXT trial is funded by CID. Dr. Carrié reported no financial relationship with the company.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies, drugs and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.

For more information, visit

Cardiovascular Research Foundation

Related Cardiovascular Research Foundation Articles from Brightsurf:

New recommendations for a thyroid and cardiovascular disease research agenda
New Recommendations for a Thyroid and Cardiovascular Disease Research Agenda have been co-published in Thyroid® and Circulation.

German Research Foundation extends funding for basic research in the neurosciences
The German Research Foundation (DFG) will be providing financial support to the Collaborative Research Center (CRC) 1080 on 'Molecular and cellular mechanisms of neuronal homeostasis' for four more years.

ASN Foundation for Kidney Research announces campaign to guarantee research funding
The ASN Foundation for Kidney Research is proud to announce the public launch of its Securing the Future Campaign during ASN Kidney Week 2016.

Malaria research at CU Anschutz receives Gates Foundation support
Kathryn Colborn, Ph.D., assistant research professor at the CU School of Medicine and senior investigator with the Center for Global Health at the Colorado School of Public Health, will pursue an innovative global health and development research project titled 'Development of an automated early warning system for malaria transmission using machine learning.'

Brain & Behavior Research Foundation honors nine for outstanding psychiatric research
The Brain & Behavior Research Foundation honored nine scientists with its 2016 Outstanding Achievement Prizes for their work in schizophrenia, mood disorders, child and adolescent psychiatry, and cognitive neuroscience.

Dr. Weber of Kessler Foundation receives Switzer Research Fellowship for TBI research
Erica Weber, PhD, of Kessler Foundation is the recipient of a Switzer Research Fellowship, awarded by the National Institute on Disability, Independent Living and Rehabilitation Research.

National Stem Cell Foundation funds neurodegeneration research at NYSCF Research Institute
The National Stem Cell Foundation and the New York Stem Cell Foundation Research Institute announced that a grant from NSCF will be used to fund NYSCF research studying how astrocytes can be manipulated to halt or prevent neurodegeneration.

AGA Research Foundation announces 2016 class of research award winners
At Digestive Disease Week® 2016, the American Gastroenterological Association (AGA) Research Foundation will honor its 2016 class of research award winners.

$2.5 million boost for lymphoma research through Tanoto Foundation
The SingHealth Duke-NUS Academic Medical Centre announced today that a S$2.5 million Tanoto Foundation Professorship in Medical Oncology has been conferred to Assoc Prof Lim Soon Thye, Head and Senior Consultant of the Division of Medical Oncology at the National Cancer Centre Singapore; and Assistant Dean at Duke-NUS Medical School.

Rex Griswold Foundation gives $50,000 to TGen for MSA research
The Rex Griswold Foundation granted $50,000 to the Translational Genomics Research Institute (TGen) to further its scientific investigation into the cause and potential treatment of a rare nerve disorder known as Multiple System Atrophy (MSA).

Read More: Cardiovascular Research Foundation News and Cardiovascular Research Foundation Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to